Monthly
$279
/mo
Flexibility with month-to-month billing.
- Compounded tirzepatide therapy
- Licensed clinician oversight
- Structured titration plan
- Care-team messaging
- Free discreet shipping
Skip to product information
Start today
Tirzepatide Weight Loss Program
Tirzepatide Therapy is designed for individuals seeking advanced support for weight loss and metabolic optimization. Tirzepatide, the active ingredient in Zepbound and Mounjaro, works by activating both GLP-1 and GIP receptors to support appetite control, blood sugar regulation, and sustainable weight management.
This next-generation treatment goes beyond willpower alone, helping support long term results through physician-guided care and personalized protocols.
- US-licensed clinicians
- Licensed US pharmacies
- Prescription required
- Free discreet shipping
Weight Loss · Dual GLP-1/GIP
The most powerful medical weight-loss tool available — with the oversight it deserves.
Tirzepatide is a once-weekly, dual-pathway incretin therapy studied for substantial weight loss and broad metabolic improvement. TruVera pairs compounded tirzepatide with licensed clinician care, structured titration, and monthly check-ins.
- Dual GIP and GLP-1 receptor agonist — activates two complementary incretin pathways for greater impact on appetite, satiety, and insulin response than GLP-1 alone
- SURMOUNT clinical trials demonstrated up to approximately 20% body-weight reduction over 72 weeks — among the largest effect sizes observed in medical weight-loss therapeutics
- Comprehensive metabolic benefits — slows gastric emptying, reduces cravings, improves post-meal blood sugar, and supports long-term appetite regulation
How it works
Your tirzepatide therapy journey in 4 steps
From intake to medication delivered — with labs, titration, and monthly clinician oversight built in.
-
Complete your intake and baseline labs
A thorough online intake captures your health history, weight-loss goals, medications, and risk factors. Baseline labs are ordered to confirm safety and establish a metabolic starting point.
-
Clinician review and treatment plan
A licensed US clinician reviews your intake and labs, and — if clinically appropriate — issues a tirzepatide prescription with a personalized titration schedule.
-
Compounded tirzepatide ships to your door
Your tirzepatide is compounded by a licensed US pharmacy and shipped in discreet, temperature-controlled packaging along with a clear titration plan and injection instructions.
-
Monthly check-ins and dose adjustments
Your clinician reviews progress, tolerability, and weight trends each month — adjusting your dose carefully as your body adapts. Message your care team anytime in between.
Pricing
Transparent tirzepatide program pricing.
One monthly price covers your clinician visits, compounded medication, titration plan, shipping, and care team access.
Most popular
Quarterly
$229
/mo
Save 18% vs monthly
Best balance of savings and commitment.
- Everything in Monthly
- Billed quarterly
- Priority clinician response
- Quarterly progress review
Annual
$199
/mo
Save 29% vs monthly
Our best price for sustained weight-loss support.
- Everything in Quarterly
- Billed annually
- Dedicated care coordination
- Annual protocol and lab review
Compounded tirzepatide is a patient-specific 503A compound, not an FDA-approved drug. Brand-name tirzepatide (Mounjaro, Zepbound) is FDA-approved. Availability of compounded tirzepatide depends on prescribing clinician judgment, evolving FDA guidance, and pharmacy sourcing. Prescriptions are only issued when medically appropriate.
Eligibility
Is tirzepatide right for you?
You may be a candidate if:
- BMI 30+ — or BMI 27+ with a weight-related comorbidity such as hypertension, pre-diabetes, or obstructive sleep apnea
- Adults 18+ committed to lasting lifestyle changes alongside medical treatment
- You've previously tried diet and exercise alone and plateaued or regained weight
- You are seeking clinician-supervised, medically guided weight loss with monthly oversight
Not right for you if:
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN-2)
- You are pregnant, trying to conceive, or breastfeeding
- History of severe gastrointestinal disease or gastroparesis (delayed gastric emptying)
- Active or recent pancreatitis, or other contraindications identified by your clinician
What is tirzepatide?
The science behind tirzepatide.
Tirzepatide is a first-in-class dual agonist — a single molecule that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Discovered by Eli Lilly researchers and approved by the FDA as Mounjaro (for type 2 diabetes, 2022) and Zepbound (for chronic weight management, 2023), tirzepatide represents the first therapeutic in its class to engage both incretin pathways at once. GIP amplifies the effects of GLP-1 on appetite and satiety, enhances insulin sensitivity in adipose tissue, and appears to contribute to the larger weight-loss effect observed relative to GLP-1–only therapies.
In the SURMOUNT-1 trial, adults with obesity (without type 2 diabetes) achieved mean body-weight reductions of roughly 15–20% over 72 weeks on the higher doses of tirzepatide, outperforming earlier GLP-1 therapies in head-to-head and indirect comparisons. The SURPASS program, studying tirzepatide in type 2 diabetes, showed substantial improvements in HbA1c along with clinically meaningful weight loss. Compared with semaglutide, tirzepatide has generally produced larger weight-loss effects in available trial data, though individual response varies.
The regulatory landscape for compounded tirzepatide has been evolving. Brand-name Mounjaro and Zepbound remain FDA-approved. Compounded tirzepatide is produced by state-licensed 503A pharmacies as a patient-specific preparation on a clinician's prescription and is not FDA-approved. Its availability has been in flux as the FDA resolves shortage determinations and related guidance, and its use depends on prescribing clinician judgment and pharmacy sourcing. TruVera provides compounded tirzepatide only when clinically appropriate, through licensed US clinicians and pharmacies.
Patient experience
Medical weight loss with actual support.
"I'd tried everything — diets, personal trainers, even semaglutide. Tirzepatide with TruVera is the first thing that actually worked. I've lost 38 pounds in six months and my hunger finally feels manageable."
Verified patient
Weight-loss progress
"The appetite difference was noticeable in the first two weeks. I'm not white-knuckling through meals anymore — I eat a reasonable portion, feel satisfied, and move on. The titration schedule kept side effects mild."
Verified patient
Appetite control
"Scale aside, my energy is up, my clothes fit, and my last labs showed better cholesterol and blood sugar. The monthly clinician check-ins made me feel like someone was actually watching my progress."
Verified patient
Non-scale wins
FAQ
Tirzepatide therapy questions
What is tirzepatide and how is it different from semaglutide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist — a single molecule that activates two complementary incretin pathways. Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor. The dual mechanism appears to enhance appetite suppression, satiety, and insulin sensitivity, and in head-to-head and indirect comparisons tirzepatide has generally produced larger weight-loss effects than semaglutide over 68–72 weeks. Individual response varies, and the right choice depends on your clinician's assessment.
Is compounded tirzepatide FDA-approved?
No. Brand-name tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Compounded tirzepatide is produced by a state-licensed 503A pharmacy as a patient-specific preparation on a clinician's prescription and is not itself FDA-approved. Availability of compounded tirzepatide has been in flux as the FDA resolves shortage determinations and related guidance. TruVera is transparent about this: prescriptions are only issued when a licensed clinician determines treatment is clinically appropriate, and availability depends on pharmacy sourcing and current regulatory posture.
How is tirzepatide taken?
Tirzepatide is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Treatment begins at a low starting dose and is gradually titrated upward every 4 weeks based on tolerability and response. Your clinician will prescribe a specific titration schedule and your pharmacy will ship prefilled syringes or vials with clear injection instructions.
When will I notice results?
Most patients notice reduced appetite and cravings within 1–2 weeks of starting treatment. Meaningful weight loss typically becomes visible by month 2–3, with the largest cumulative results occurring over 6–18 months of consistent treatment and titration. In trials, average peak weight loss was observed around 72 weeks. Your clinician will track progress monthly and adjust the plan as needed.
What are the side effects?
The most common side effects are gastrointestinal: nausea, reduced appetite, diarrhea, constipation, and occasional vomiting, particularly during dose increases. These usually improve with time and careful titration. Less common but important risks include pancreatitis (tirzepatide should be stopped if symptoms arise), gallbladder issues, and hypoglycemia when combined with insulin or sulfonylureas. Tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodents — it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. Your clinician will review your full history before prescribing.
Can I pause or cancel my subscription?
Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. Because tirzepatide should typically be tapered rather than stopped abruptly if you've reached higher doses, we recommend messaging your care team before canceling so we can help plan a safe off-ramp.